In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include: An overview of the PROpel study of olaparib and the TRITON study of rucaparib FDA-approved indications for olaparib and rucaparib Genetic and molecular testing for BRCA1/2 and other HRR mutations Managing adverse events associated with ...
Jun 30, 2022•12 min•Ep. 61
In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events. Topics include: Currently approved ICIs Role of biomarker and PD-L1 testing in advanced NSCLC Strategies to individualize ICI treatment for patients with advanced NSCLC Strategies for identifying and managing immune-related adverse events in patie...
Jun 30, 2022•13 min•Ep. 60
In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include: An overview of the monarchE study leading to FDA approval of adjuvant abemaciclib Key trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancer Managing adverse events associated with CDK4/6 inhibitors Promoting adherence to oral ther...
Jun 30, 2022•21 min•Ep. 63
In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include: Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLC Updated survival and safety results after 5 years from the phase III Checkmate 227 s...
Jun 27, 2022•20 min•Ep. 62
In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes. Presenters Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane Heart and Vascular Institute Tulane University School of Medicine New Orleans, Louisiana David S. Kountz, MD Professor of Medicine...
Jun 16, 2022•15 min•Ep. 58
In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes. Presenters Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane Heart and Vascular Institute Tulane University School of Medicine New Orleans, Louisiana David S. Kountz, MD Profess...
Jun 16, 2022•13 min•Ep. 57
In this podcast episode, 2 migraine experts discuss clinical pearls for individualizing migraine care from diagnosis to ongoing management. They cover patient factors to consider in the differential diagnosis, when choosing an acute treatment, and in making the decision to initiate preventive treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine . Contributors Maureen Moriarty, DNP, ANP-BC Associate Professor Director Malek School of Nursing Professions Ma...
Jun 13, 2022•23 min•Ep. 59
This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and full program at: PCE.is/NVAF . Contributors: Program Director Keith...
May 26, 2022•12 min•Ep. 54
This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study. Review the downloadable slideset and full program at: PCE.is/NVAF . Contributors: Program Directo...
May 26, 2022•21 min•Ep. 56
This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF. Review the downloadable slideset and full program at: PCE.is/NVAF . Contributors: Progra...
May 26, 2022•18 min•Ep. 55
This podcast is the last in a series of four featuring IBD Dr Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, Dr Bernasko reviews the best practices for collaborating with primary care for optimal health maintenance in IBD patients, including cancer screening, bone health, immunizations, and more. Presenter: Nana Bernasko, DNP, CRNP, WHNP-BC Assistant Professor Division of Gastroenterology and Hepatology Department of Medicine Penn State University Medical Center Hershey, Pennsylvania The co...
May 16, 2022•18 min•Ep. 50
This podcast is the third in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, our panel of experts review strategies for individualizing care, medication response challenges, the use of therapeutic drug monitoring, and treatment de-escalation strategies. Presenters: Anita Afzali, MD, MPH, FACG, AGAF Professor of Clinical Medicine Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease Medical Dire...
May 16, 2022•17 min•Ep. 49
This podcast is the second in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. Our moderator for the series is Mr Rick Davis, PA-C. In this episode, our panel of experts review available medication options and their current place in therapy according to recent evidence and guideline recommendations. Presenters: Anita Afzali, MD, MPH, FACG, AGAF Professor of Clinical Medicine Abercrombie & Fitch Endowed Chair in Inflammato...
May 16, 2022•22 min•Ep. 48
This podcast is the first in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, the experts discuss the importance early and accurate diagnosis and classification of IBD plays in choosing appropriate and individualized therapies for disease management. Presenters: Anita Afzali, MD, MPH, FACG, AGAF Professor of Clinical Medicine Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease Medical Director...
May 16, 2022•24 min•Ep. 47
In this second of two podcasts, 2 experts in migraine provide clinical pearls focused on preventing migraine. Listen as they discuss patient factors that indicate preventive treatment is warranted, the range of available preventive treatments and their use in practice, and strategies for engaging patients in their care. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine . Contributors: Karen A. Williams, DNP, FNP-BC, AQH President KDW Health Management Pensacola, ...
Apr 05, 2022•27 min•Ep. 44
In this first of two podcasts, 2 experts in migraine provide valuable information on the differential diagnosis of migraine, including screening tools and techniques to incorporate into your practice. Additionally, they detail acute treatment options ranging from nonpharmacologic to over-the-counter to novel prescription pharmacologic therapies and discuss their use in the acute migraine management paradigm. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine . Con...
Apr 05, 2022•27 min•Ep. 41
In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP . Contributors: Hanny Al-Samkari, MD Assistant Professor Harvard Medical School Attending Hematologist and Clinical Investigator Division of Hemato...
Apr 05, 2022•13 min•Ep. 46
In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP . Contributors: Hanny Al-Samkari, MD Assistant Professor Harvard Medical School...
Apr 05, 2022•15 min•Ep. 45
In this second of 2 podcasts episodes on the management of painful vaso-occlusive crises in patients with sickle cell disease, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient setting recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selecting blocking antibody crizanlizumab. This activity is availabl...
Apr 04, 2022•12 min•Ep. 39
In this first of 2 podcasts episodes, Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss best practices for the management of painful vaso-occlusive crises (VOCs) in patients with sickle cell disease, review the disease pathophysiology, and provide emergency department and outpatient setting recommendations on nonpharmacologic and pharmacologic management of painful VOCs. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmac...
Apr 04, 2022•15 min•Ep. 38
In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for met...
Mar 21, 2022•33 min•Ep. 42
In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Joleen Hubbard MD Cathy Eng, MD Stephanie Andrews, MS, APRN-C Ms Andrews: fees for non-CME/CE services: Genentech. Dr Eng: ...
Mar 21, 2022•24 min•Ep. 43
In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu . Contributors: Dr Morgans has disclosed that she has received funds for research support f...
Mar 17, 2022•28 min•Ep. 40
In this second of two podcasts, an expert discuss decision making for subsequent line therapy for advanced gastric cancer, and review cases to illustrate practical considerations, followed by a question-and-answer session. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributor: David Ilson, MD Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho....
Feb 25, 2022•23 min•Ep. 37
In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributor: David Ilson, MD Dr Ilson: consulting fees: Aeris, Amgen, Aste...
Feb 25, 2022•29 min•Ep. 36
In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Amit Singal, MD, MS Mark Yarchoan, MD Bridget O’Brien, DNP, FNP-BC, ...
Feb 25, 2022•33 min•Ep. 34
In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Amit Singal, MD, MS Mark Yarchoan, MD Bridget O’Brien, DNP, FN...
Feb 25, 2022•31 min•Ep. 35
In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Arjun Balar, MD Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, S...
Feb 11, 2022•31 min•Ep. 32
In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributors: Arjun Balar, MD Rana R. McKay, MD Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/...
Feb 11, 2022•37 min•Ep. 33
In this second of two podcasts, Rana R. McKay, MD, and Arjun Balar, MD, and moderator Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN, discuss the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-resistant or castration-sensitive prostate cancers, including the use of taxanes, androgen receptor agonists, and other therapies. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU . Contributor: Arjun Balar, MD...
Feb 10, 2022•31 min•Ep. 31
